SFA Therapeutics

SFA Therapeutics is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in Jenkintown, Pennsylvania. The company utilizes a proprietary deuteration platform to develop oral, small-molecule biosynthetic compounds derived from short-chain fatty acids. Its core technology is designed to reset the immune system by modulating inflammatory factors through the gut-immune axis, specifically targeting the differentiation of T-regulatory (Treg) cells. By creating patentable new chemical entities, SFA aims to provide therapeutic solutions for chronic inflammatory, autoimmune, and oncological conditions. The company’s pipeline includes nine drug candidates, with its lead asset, SFA-002, currently being evaluated for the treatment of psoriasis.

This technology addresses significant unmet needs in markets such as psoriasis, metabolic dysfunction-associated steatohepatitis (MASH), and various cancers, offering a potential alternative to treatments that rely on chronic immune suppression. SFA Therapeutics has demonstrated early clinical proof-of-concept through positive Phase 1b trial data for SFA-002, which showed significant efficacy and a clean safety profile. Supported by an extensive intellectual property portfolio comprising granted and pending patents, the company is actively advancing its pipeline toward Phase 2 clinical trials and seeking strategic partnerships to accelerate the development and commercialization of its immunomodulatory therapeutics.